Actively Recruiting
Phase 3 Randomized Study to Evaluate Fenfluramine Hydrochloride Versus Placebo in Rett Syndrome with Open-Label Extension
Led by UCB BIOSCIENCES, Inc. · Updated on 2026-11-02
200
Participants Needed
40
Research Sites
133 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of fenfluramine hydrochloride compared to a placebo in people with Rett syndrome, a genetic neurological disorder. This Phase 3 clinical trial aims to assess how well fenfluramine hydrochloride works and its safety in improving symptoms of Rett syndrome, with outcomes measured by changes in behavior and clinical impressions over 14 weeks. Participants receive fenfluramine hydrochloride or placebo orally during a 14-week double-blind period, including dose adjustment and maintenance. After this, all participants enter a 2-week transition period, then a 52-week open-label phase where they receive fenfluramine hydrochloride. Those who stop treatment without continued access undergo an 8-day medication taper and a 26-week follow-up. Throughout the trial, participants undergo assessments including questionnaires on behavior, sleep, communication, and caregiver impressions, as well as heart monitoring via ECG and echocardiograms to watch for side effects. Safety and adverse events are tracked up to nearly four years. The study involves regular visits during treatment and follow-up periods, aiming to measure changes in Rett syndrome symptoms and overall clinical status.
CONDITIONS
Brief Title
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
Research Team
U
UCB Cares
U
UCB Cares
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here